

**CA 15.3; BREAST CANCER  
MARKER, SERUM  
(CMIA)**

**U/mL**

**< 30.00**

**Note:** 1. This test is not recommended to screen Breast cancer in the general population.

2. False negative / positive results are observed in patients receiving mouse monoclonal antibodies for diagnosis or therapy.

3. Patients with confirmed Breast cancer may show normal pre-treatment

CA 15.3 levels. Hence this assay, regardless of level, should not be interpreted as absolute evidence for the presence or absence of malignant disease. The assay value should be used in conjunction with findings from clinical evaluation and other diagnostic procedures.

**Clinical Use**

- An aid in the management of Breast cancer patients. It is useful in monitoring therapy and progression in Metastatic Breast cancer patients. A significant increase in levels must be at least 25% that correlates with disease progression in 90% of the patients. A decrease of at least 25% in levels correlates with regression of the disease in 78% of patients
- Predict recurrence in patients with stage II / III Breast carcinoma

<b>DISEASE</b>	<b>PERCENTAGE POSITIVITY OF CA 15.3</b>
Primary Breast Cancer	23
Metastatic Breast Cancer	69
Pancreatic Cancer	80
Lung Cancer	71
Ovarian Cancer	64
Colorectal Cancer	63
Liver Cancer	28
Benign Liver Disease	42
Benign Breast Disease	16